More importantly, this study proposes that targeting Mettl3 might bring profound influence on conquering chemotherapy resistance and immunotherapy tolerance caused by tumor angiogenesis, offering therapeutic alternatives to patients suffering this treatment dilemma. The gene discussed is METTL3; the disease is neoplasm.